Document is current

Article History

Accepted: 15 May 2025

First Online: 24 June 2025

Declarations

:

: No external funding was used in the preparation of this manuscript.

: PR has served on an advisory board in a personal capacity for Blueprint Medicines; has served as an invited speaker and on an advisory board in a personal capacity and received honoraria for lectures from BMS, MSD, and Pierre Fabre; has served as an invited speaker and on an advisory board in a personal capacity for Merck and Sanofi; has served as an invited speaker in a personal capacity for Novartis; has received funding and a research grant to his institution from, and has a financial interest in, BMS; has received a research grant to his institution, has a financial interest in, and has received a research grant for ISS from Pfizer; serves as an officer for the American Society of Oncology; and is a member of the board of directors of the Polish Society of Surgical Oncology. AMC, ŁG, RD, NKK, KG, BCS, JM, MZięt, GKW, KK have delivered lectures for and received fees, honoraria, and travel accommodations from BMS, MSF, and Pierre Fabre. PT, KO, PB, and MZiel have no conflicts of interest that might be relevant to the contents of this manuscript.

: Patients were treated under National Treatment Reimbursement Program B.59 as per the Announcement of the Minister of Health. All patients signed informed consent for the treatment. Data analysis was approved by the local ethical committee in Maria Sklodowska-Curie National Research Institute of Oncology (approval no. KB/430-74/20 from October 23, 2020).

: All patients signed informed consent for the treatment, data processing, utilization for scientific research purposes, and publication.

: All patients signed informed consent for the treatment, data processing, utilization for scientific research purposes, and publication.

: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

: The code created and used during the current study is available from the corresponding author on reasonable request.

: Conceptualization: AMC, PT, KO, and PR. Methodology: AMC, PT, and PR. Software: AMC and PT. Data curation: AMC, KO, and PB. Investigation: all authors. Validation: AMC, PT, KO, and PB. Formal analysis: PT, AMC, and PR. Supervision: AMC and PR. Funding acquisition: PR. Visualization: PT. Project administration: AMC. Resources: AMC and PR. Writing – original draft: AMC, PT, PB, and PR. Writing – review and editing: all authors.